TD Cowen analyst Yaron Werber has maintained their bullish stance on SEPN stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Yaron Werber has given his Buy rating due to a combination of factors that highlight Septerna, Inc.’s promising future. The recent collaboration with Novo Nordisk, valued at up to $2.2 billion, not only validates Septerna’s GPCR Native Complex platform but also significantly extends the company’s cash runway beyond 2028. This partnership is expected to reduce research and development expenses as Novo Nordisk will fully fund the development efforts.
Additionally, Septerna is on track to advance its PTH1R agonist to Phase 1 trials by the end of 2025, and the SEP-631 (MRGPRX2 NAM) program is progressing ahead of schedule, with Phase 1 trials now set to begin in the third quarter of 2025. These developments, coupled with the potential for milestone payments and royalties from the Novo collaboration, position Septerna as a strong investment opportunity with a promising pipeline and strategic partnerships.